PCSK9 and peripheral arterial disease: Indeed, it has been shown by Bonaca et al. from the FOURIER trial that PAD patients have the highest absolute risk reduction by the PCSK-9 inhibitor Evolocumab and thus the lowest number-needed-to-treat (NNT) [30].